News
Article
On March 10, 2021, the U.S. Food and Drug Administration (FDA) approved tivozanib for adult patients with relapsed or refractory (R/R) advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.
Read the FDA announcement.
Read AVEO Oncology's announcement.
Posted 3/11/2021